Yahoo! Finance: COR News

CORTEX PHARMACEUTICALS INC/DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule (EDGAR Online)

Fri, 11 Dec 2009 22:16:09 Etc/GMT

Cortex Receives Delisting Notification from NYSE Amex (Business Wire)

Wed, 9 Dec 2009 13:30:00 Etc/GMT

IRVINE, Calif.----Cortex Pharmaceuticals, Inc. announced that it has received notification from the NYSE Amex LLC indicating that, due to the Company’s non-compliance with certain continued listing standards as previously reported, the Exchange intends to delist the Company’s common stock from the NYSE Amex effective as of the close of business on Friday, December 11, 2009.

CORTEX PHARMACEUTICALS INC/DE/ Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, F (EDGAR Online)

Tue, 24 Nov 2009 17:31:06 Etc/GMT

CORTEX PHARMACEUTICALS INC/DE/ Financials (EDGAR Online Financials)

Sat, 21 Nov 2009 18:04:19 Etc/GMT

CORTEX PHARMACEUTICALS INC/DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement (EDGAR Online)

Mon, 16 Nov 2009 21:02:46 Etc/GMT

Cortex Reports Third Quarter Operating Results (Business Wire)

Mon, 16 Nov 2009 13:30:00 Etc/GMT

IRVINE, Calif.----Cortex Pharmaceuticals, Inc. (NYSE Amex ) reported a net loss applicable to common stock of $3,243,000, or $0.06 per share for the quarter ended September 30, 2009 compared with a net loss applicable to common stock of $3,148,000, or $0.07 per share for the corresponding prior year period.

Depression Treatments Reviewed by NeuroInvestment (Marketwire)

Wed, 4 Nov 2009 17:34:00 Etc/GMT

CEO Interview, Cortex Pharmaceuticals, Inc. - Dr. Mark Varney (Wall Street Transcript)

Mon, 2 Nov 2009 20:01:00 Etc/GMT

67 WALL STREET, New York - November 2, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This 76-page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Alzheimer's Therapeutics Reviewed by NeuroInvestment (Marketwire)

Thu, 3 Sep 2009 15:55:00 Etc/GMT

CORTEX PHARMACEUTICALS INC/DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule (EDGAR Online)

Fri, 21 Aug 2009 15:44:30 Etc/GMT

CORTEX PHARMACEUTICALS INC/DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement (EDGAR Online)

Fri, 14 Aug 2009 17:25:33 Etc/GMT

CORTEX PHARMACEUTICALS INC/DE/ Files SEC form 10-Q, Quarterly Report (EDGAR Online)

Fri, 14 Aug 2009 10:06:29 Etc/GMT

CORTEX PHARMACEUTICALS INC/DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of E (EDGAR Online)

Thu, 30 Jul 2009 12:02:18 Etc/GMT

CORTEX PHARMACEUTICALS INC/DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule (EDGAR Online)

Fri, 22 May 2009 20:12:51 Etc/GMT

CORTEX PHARMACEUTICALS INC/DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement (EDGAR Online)

Fri, 15 May 2009 17:17:45 Etc/GMT

CORTEX PHARMACEUTICALS INC/DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments to Articles (EDGAR Online)

Fri, 17 Apr 2009 17:42:36 Etc/GMT

CORTEX PHARMACEUTICALS INC/DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement (EDGAR Online)

Wed, 15 Apr 2009 16:43:24 Etc/GMT

CORTEX PHARMACEUTICALS INC/DE/ Files SEC form 10-K, Annual Report (EDGAR Online)

Wed, 15 Apr 2009 10:09:11 Etc/GMT

CORTEX PHARMACEUTICALS INC/DE/ Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Other Events, F (EDGAR Online)

Thu, 19 Mar 2009 20:18:33 Etc/GMT

CORTEX PHARMACEUTICALS INC/DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or (EDGAR Online)

Tue, 23 Dec 2008 11:03:52 Etc/GMT